Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
Abbreviated, Albright, ANDA, assuming, AstraZeneca, attention, AZ, cell, Certificate, certification, COVID, Disposition, divert, dosage, drawn, duly, embedded, enforce, exhibit, experienced, Extraordinary, formatted, hold, infringement, inherent, Inline, instance, Interbank, Involuntary, Judge, jurisdiction, Label, law, licensor, Linkbase, London, mandatory, Maximo, mediated, meeting, mg, monetary, noncompliance, notifying, omitted, osimeritinib, osimertinib, Page, principle, provision, restructuring, salary, Sandoz, Schema, Secretary, Stuart, successor, suit, TAGRISSO, Taxonomy, Therapeutic, thereunto, threshold, twelve, undersigned, variety, write, XBRL
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view